RMi evaluates companies in the stem, cell and gene therapy RegMed (SCGT&RM) sector and dissecting its claims; separating fact from science fiction and validating the integrity of their existence. RMi carefully vets a "tight" synthesis that identifies the event orientation in the SCGT&RM sector while measuring its impact on comparables and markets thus making a prognostication to the pricing of the event and its effect upon valuation.
January 31, 2017
Regenerative Medicine Earnings Scorecard - Q4/2016 - to date
November 2, 2016
Regenerative Medicine Earnings Scorecard - Q3/2016 - to date
August 4, 2016
Regenerative Medicine Earnings Scorecard - Q2/2016 - to date
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors